Bladder cancer is ranked the ninth most frequently occurring type of cancer, especially in men. Countries in Southern and Western Europe, Northern Africa, Western Asia, and North America have higher number of recorded cases for bladder cancer in men. Bladder cancer can occur to persons from any age group; however, those above 50 years of age have more chances of acquiring this cancer. Thus, the growing geriatric population across the globe is acting as a driver for the global bladder cancer market. Schistosoma haematobium infection also causes bladder cancer among selected population.

Some of the other factors encouraging the growth of this market include, government initiatives towards helping patients get effective treatments, growing awareness about bladder cancer among the masses, and growing healthcare expenditure. On the other hand, inaccurate diagnosis is a hurdle for this market. Expensive diagnosis is another factor, which may dampen the growth of the bladder cancer market. Additionally, availability and high use of generic drugs are slowing the growth of the market. Moreover, patent expirations are also behind the decline in the pace of growth of the market.

On the basis of geography, the market is led by North America owing to high prevalence of bladder cancer, highly advanced healthcare infrastructure, growing concern regarding bladder issues, and use of innovative healthcare solutions. Apart from North America, Asia Pacific is anticipated to exhibit robust growth in the bladder cancer market. Asia Pacific is projected to show a high growth on account of increasing awareness about diseases of the bladder and emerging innovative diagnostic options and effective treatments. Many players are finding Asia Pacific an attractive market for investing, thus, the market in the region is set to grow in the years to come.

Some of the leading players operating in the glpbal bladder cancer market are: Eli Lilly and Co., Bristol-Myers Squibb, AstraZeneca plc, Celgene Corporation, Sanofi, F. Hoffmann-La Roche, Novartis International AG, GlaxoSmithKline plc, and Pfizer Inc.

Browse Report on Bladder Cancer Market –